Sites Menu > APS - Lupus Research & Trials Information

APS - Lupus Research & Trials Information

NIH Office of Rare Diseases

Online resources and databases on completed current, or planned rare disease studies. If you enter the Web sites listed below, you will leave the ORD Web site. Please return to our Web site to find more information on rare diseases, patient support groups, and genetic testing laboratories and clinics.

Identifying Unexplored Domains of Quality of Life in Lupus Patients

Study to identify facets of daily life that have been impacted upon by lupus that are not routinely evaluated in studies of quality of life in adults with lupus. Sponsors: Mary Kirkland Center for Lupus Research. Principal Investigator: Melanie J. Harrison, MD, MS. HSS IRB #: 21067

APLASA-P Study: Determining the Role of Aspirin in the Management of Antiphospholipid Syndrome Patients who Present Only with Pregnancy Morbidity

An international multi-center, observational study designed to study whether low-dose aspirin can prevent blood clots in APS patients who have only had miscarriages but no blood clots in other vessels. Sponsors: Bayer Pharmaceuticals, Arthritis Foundation, New York Chapter. Principal Investigator: Doruk Erkan, MD. HSS Co-investigators: Melanie J. Harrison MD, MS, Michael D. Lockshin, MD, Lisa Sammaritano, MD, Margaret Peterson, PhD. HSS IRB #: 20069

Clinical Trials Information for Patients

In medical research, a clinical trial is an organized study conducted in people with a disease or condition to answer specific questions about a new treatment or a new way of using a known treatment. Each study tries to increase medical knowledge and to find new and better ways to help patients. Besides studying new drugs, clinical trials study new combinations of drugs already used in treatment, new ways of giving treatment, and how changes in lifestyle can help patients or prevent diseases from occurring. Other clinical trials compare the best known standard therapy with a newer therapy to see if one produces more cures and causes fewer side effects than the other.

Quality of Life in Pediatric SLE

Study to determine what characteristics of childhood lupus are associated with decreased quality of life. Sponsors: Hospital for Special Surgery, Department of Pediatrics Principal Investigator: Lakshimi Moorthy, MD and Thomas Lehman, MD. Co-investigators: Melanie J. Harrison, MD, MS, Margaret Peterson, PhD.

A Pilot Study of a Cognitive Rehabilitation Intervention Program in Systemic Lupus Erythematosus (SLE) Patients

Study of a novel group educational program for lupus patients to improve their ability to perform everyday tasks that have become difficult due to cognitive dysfunction. Sponsor: Mary Kirkland Center for Lupus Research. Principal Investigator: Melanie J. Harrison, MD, MS. HSS IRB #: 22076

Rare Diseases Clinical Research Network

The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease risk, disease severity and activity, and clinical outcome, while also encouraging development of new approaches to diagnosis, prevention, and treatment.

Clinical provides regularly updated information about federally and privately supported clinical research in human volunteers. gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. Before searching, you may want to learn more about clinical trials.

Lupus Research Institute

Recognizing that most major medical breakthroughs come from unexpected directions, the LRI fosters and supports only the highest ranked new science to prevent, treat and cure lupus. Millions in private sector funding support more than 50 scientists pursuing basic and clinical research studies at leading medical institutions around the country.

Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus

Purpose: Some newborns are born with congenital heart block (CHB), a condition occurring in babies with neonatal lupus. The first part of the study will test the effectiveness of fluorinated steroids, including dexamethasone, in improving the heart function and general health of newborns who have auto-antibody-associated CHB. The second part of this study will use ultrasound and heart monitoring to observe high-risk pregnant women and their fetuses during the third trimester of pregnancy.

CDC Hemostatis and Thrombosis Center Pilot Site Locations

The Centers for Disease Control and Prevention supports a network of specialized health-care centers to prevent and reduce complications experienced by persons with certain hereditary blood disorders. Currently, CDC has provided funds to eight "pilot" hemostatis and thrombosis centers to find out how to best provide treatment and preventative care to people with thrombosis or thrombophilia. These centers have multi-disciplinary teams of health-care specialists, state-of-the art clinical research programs, and provide outreach and education programs for patients.

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

This study is currently recruiting patients. Verified by Hospital for Special Surgery, New York September 2005


Human Genome Sciences, Inc. announced that a Phase 2 clinical trial demonstrated that LymphoStat-B™ (belimumab) significantly reduced disease activity in patients with serologically active systemic lupus erythematosus (SLE), exhibited clinically relevant bioactivity, and was safe and well tolerated. Two oral presentations reported the complete study results today in Amsterdam at the Annual European Congress of Rheumatology (EULAR 2006).

The Alliance for Lupus Research

Lupus Clinical Trials

Our goal is to get as many people enrolled in lupus clinical trials as possible, so that the lupus community can finally get some answers on prevention, treatments, and a cure.

Antiphospholipid Syndrome Studies/Research

One fast click to see the current studies dealing with APS.

Lupus Research Institute - Chicago

The LRI Chicago shares the mission of its lead organization, the Lupus Research Institute, in championing only new science — the truly innovative research that will prevent, treat and cure lupus.

Information for Potential Participants of the Genetics of Venous Thrombosis Study

Why is this study being done? The purpose of this study is to determine inherited causes of venous thromboembolism(includes both deep vein thrombosis and pulmonary embolism) by studying families in whom two or more family members have had either deep vein thrombosis or pulmonary embolism.

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

Lupus, Volume 15, Number 9, September 2006, pp. 577-583(7). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE.

Clinical Trials: Strokes

Research will evaluate whether study medication will affect breathing, relax tightness in the muscles, and allow the wrist, fingers, and elbow to be straightened. Study will last for about 32 weeks; if you participate you will be asked to make nine visits to the study center, where you will have injections into your arm and hand. Research site located in Pittsburgh, Penn.

The State of Lupus Research

Genetics of antiphospholipid antibody syndrome (APS): Study #1

We know very little about what causes antiphospholipid antibody syndrome (APS). Sometimes several family members have APS. Other times, one person has APS and other relatives have a different autoimmune disease like lupus or diabetes. Because APS sometimes runs in families, we think that certain genes may cause APS. The purpose of this study is to find the genes that cause APS.

Stroke Trials Directory

Welcome to the Stroke Trials Directory, a continuously updated registry of randomized clinical trials. This project is a joint effort of the Internet Stroke Center at Washington University School of Medicine, the American Stroke Association and the National Institute of Neurological Disorders and Stroke. Please visit our frequently asked questions page for more information about this site.

Pregnancy Complications & APS

Antiphospholipid antibody syndrome (APS) is a medical problem that is associated with health risks for the pregnant mother and her baby. Initial selection criteria for the study include women between 18 and 44 years of age, diagnosis of antiphospholipid antibody syndrome and able to safely undergo treatment with heparin. Research site located in Chicago, Ill.



Search our Sites


[1] [2] Next

AUTOMATE your Links Pages with!



The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2011 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295